source
- Biopharma chases new immunology targets as Humira and Dupixent set high barJohnson & Johnson, Pfizer, Argenx and several other companies are expanding their immunology pipelines, seeking new targets and improvements to capture part of the market driven by AbbVie’s Humira…
- Merck and Daiichi withdraw lung cancer ADC filing after FDA says data insufficientMerck and Daiichi Sankyo have pulled their application for accelerated approval of a B7-H3-directed antibody-drug conjugate aimed at extensive-stage small cell lung cancer. The FDA indicated that…